McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
4 Sector ETFs & Stocks to Bet on Q4 Earnings
by Sweta Killa
Sectors with positive earnings growth in Q4 include autos (86.3% earnings growth), construction (27.2%), basic materials (7.6%), medical (6.3%), and aerospace (4.4%).
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021
by Urmimala Biswas
Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
AmerisourceBergen (ABC), WBA Ink Deal to Focus on Core Arms
by Zacks Equity Research
AmerisourceBergen (ABC) and Walgreens (WBA) enter into a key strategic deal to boost focus on core businesses, while extending their partnership.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
Why You Should Retain Veeva (VEEV) in Your Portfolio Now?
by Zacks Equity Research
Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
by Zacks Equity Research
Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
OPKO Health's (OPK) BioReference Starts Fan Testing Program
by Zacks Equity Research
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
MCK or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
5 Stocks That Could Hit Several New Highs in 2021
by Sandip Chakraborty
Given the upbeat sentiments in the market, FedEx (FDX), Deere (DE), D.R. Horton (DHI), Fortescue (FSUGY) and Fiat Chrysler (FCAU) are expected to give good returns to investors in 2021.
Here's Why You Should Hold on to Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System. But weak operational performance is a woe.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
by Zacks Equity Research
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
HMS Holdings (HMSY) to be Acquired by Gainwell for $3.4B
by Zacks Equity Research
HMS Holdings (HMSY) entered into an agreement to be acquired by Gainwell in an all-cash transaction deal worth about $3.4 billion.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.